DAR ES SALAAM, Tanzania -- When Yusta Michael (not her real name) unintentionally fell pregnant in the first year of her university, she realised her dreams had been shattered. A hard-working student at the Institute of Social Welfare in Tanzania’s largest commercial city, Michael was aspiring to become a social worker and help addressing the plight of street children in the sprawling city. At three months pregnant, Michael decided to terminate the pregnancy because her boyfriend disowned it, and she didn’t want to disappoint her deeply religious parents. Continue reading ->
Some 60 percent more Africans die from cancer than malaria, and the number of cancer deaths is expected to increase almost 70% by 2030, according to experts. Breast, cervical, prostate, lymphoma and colorectal constitute the top five cancers diagnosed on the continent. In order to address this emerging cancer crisis, the African Access Initiative (AAI) was launched over a year ago. Continue reading ->
Or they should be. That’s the conclusion of a recent study published in the medical journal Vaccine. The study focused on political views of parents in the state of California, who had chosen not to vaccinate their nursery-school aged children. And it tracked the number of parents who had filed personal belief exemptions (PBEs), applications for permission to avoid vaccinations over a 5-year period to 2015. A disproportionate number of parents filing such forms were from Republican or conservative neighbourhoods, according to researcher Kevin A Estep, from the health administration and policy program at the university. Continue reading ->
This week the media reported that the Brazilian federal court removed the patent protection for eculizumab, sold under the brand name Soliris by Alexion Pharmaceuticals Inc. Eculizumab is used in the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disease. The product was approved by the US FDA for this indication in 2016. Brazil’s health care system spent $184.2 million to treat 442 patients with Soliris, an average of over $416,000 per patient. The patent office expects that more revocations may follow. This blog explains why this is. Continue reading ->
TAIPEI, Taiwan - Two years after the victory of Taiwan Democratic Progressive Party (DPP) and President Tsai Ing-wen, Taiwan is feeling the effects of the DPP's position against the "One China principle." At the World Health Organization, China is allegedly successfully blocking Taiwan from participating in the annual World Health Assembly, and in a number of WHO technical meetings, officials say. Beyond the political dimension of the dissent between China and Taiwan, the situation may hurt the Taiwanese and global health security, Taiwanese officials said. Continue reading ->
Pharmaceutical R&D constantly leads to the generation of new intellectual property (IP), from clinical trial data to libraries of promising compounds. Not all IP assets generated by a company are used in their future R&D. When this happens, companies can choose instead to share them with other third-party researchers, under licensing agreements. The Access to Medicine Foundation has worked with BIO Ventures for Global Health (BVGH) to develop a framework for identifying which IP assets are most difficult for companies to share, yet most likely to speed up R&D of the medicines and vaccines needed by people living in low- and middle-income countries (LMICs), write Clarke B. Cole and Katie Graef. Continue reading ->